Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPOWER-2: TSND-201 for PTSD
NCT07836647Phase 3Recruiting
- Sponsor
- Transcend Therapeutics
- Start
- Sep 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of TSND-201 in post-traumatic stress disorder (PTSD) (3 arms), sponsored by Transcend Therapeutics. Primary endpoint: Clinician-Administered PTSD Scale for DSM-5 Total Severity Score at 12 weeks. Started Sep 2026; status: recruiting.
02
Drugs
TSND-201
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT07836647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07836647.